Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

In this prospective, genomics-driven study of rucaparib in mCRPC, we found limited radiographic/PSA responses to PARP inhibition in men with alterations in <i>ATM, CDK12</i>, or <i>CHEK2</i>. However, patients with alterations in other DDR-associated genes (e.g., <i>PALB2</i>) may benefit from PARP inhibition.<i>See related commentary by Sokolova et al., p. 2439</i>.